Skip to main content

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model





) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 0.3%. By the end of trading, Aetna rose 72 cents (1.6%) to $44.26 on average volume. Throughout the day, 3.7 million shares of Aetna exchanged hands as compared to its average daily volume of 4.5 million shares. The stock ranged in a price between $43.39-$44.28 after having opened the day at $43.50 as compared to the previous trading day's close of $43.54. Other companies within the Health Care sector that increased today were:




), up 54.5%,

Thermogenesis Corporation



), up 17.6%,



Scroll to Continue

TheStreet Recommends


), up 15.4%, and




), up 15.4%.

  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

Aetna Inc. operates as a diversified health care benefits company in the United States. The company operates in three segments: Health Care, Group Insurance, and Large Case Pensions. Aetna has a market cap of $14.81 billion and is part of the health services industry. The company has a P/E ratio of 8.7, equal to the average health services industry P/E ratio and below the S&P 500 P/E ratio of 17.7. Shares are up 3.2% year to date as of the close of trading on Friday. Currently there are 10 analysts that rate Aetna a buy, no analysts rate it a sell, and eight rate it a hold.

TheStreet Ratings rates Aetna as a


. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, attractive valuation levels, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front,

Dehaier Medical Systems



), down 20.4%,




), down 9.7%,

Arrhythmia Research Technology



), down 9.1%, and

BioDelivery Sciences International



), down 8.9%, were all laggards within the health care sector with

Arena Pharmaceuticals



) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR



) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care




FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge!

Free download now